Kotaro Nagase

Kotaro Nagase

Saga, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma.

Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma.

Journal: The British journal of dermatology

Published: September 22, 2025

Effectiveness and Prognosis of Systemic Chemotherapy for Unresectable Malignant Apocrine and Eccrine Tumors: A Real-World Multicenter Retrospective Study.

Effectiveness and Prognosis of Systemic Chemotherapy for Unresectable Malignant Apocrine and Eccrine Tumors: A Real-World Multicenter Retrospective Study.

Journal: JCO global oncology

Published: September 12, 2025

Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Merkel Cell Carcinoma 2025.

Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Merkel Cell Carcinoma 2025.

Journal: The Journal of dermatology

Published: August 04, 2025

Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor responders.

Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor responders.

Journal: Communications medicine

Published: March 07, 2025

Upper arm bronchogenic cyst: A rare case presentation.

Upper arm bronchogenic cyst: A rare case presentation.

Journal: European journal of dermatology : EJD

Published: August 18, 2023

Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance.

Safety and effectiveness of avelumab in patients with Merkel cell carcinoma in general clinical practice in Japan: Post-marketing surveillance.

Journal: The Journal of dermatology

Published: July 19, 2023

Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients.

Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients.

Journal: Frontiers in medicine

Published: May 31, 2023

Ⅰ. Present and Future of Treatment Focusing on Systemic Therapy against Merkel Cell Carcinoma

Ⅰ. Present and Future of Treatment Focusing on Systemic Therapy against Merkel Cell Carcinoma

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: April 17, 2023

Improvement of ixekizumab-related interstitial pneumonia following its discontinuation in a patient with psoriatic arthritis

Improvement of ixekizumab-related interstitial pneumonia following its discontinuation in a patient with psoriatic arthritis

Journal: European journal of dermatology : EJD

Published: July 22, 2022

Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.

Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 12, 2022

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).

Journal: ESMO open

Published: September 21, 2021

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 21, 2021

Showing 1-12 of 49

Last Updated: 09/26/2026